Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2012

01-07-2012 | Editorial

Bin1: A New Player in IBD Barrier Dysfunction

Authors: Hyunji Ryu, Daniela Posca, Terrence Barrett

Published in: Digestive Diseases and Sciences | Issue 7/2012

Login to get access

Excerpt

The ability of the host to regulate permeability of the intestinal barrier is a critical determinant of host defense. Regulation of permeability occurs at the level of epithelial tight junctions (TJ). TJ are composed of transmembrane proteins, such as occludin, claudin, and JAM family proteins. Plaque proteins, such as zonula occludins (ZO), connect the TJ complex to F-actin and actomyosin rings regulating cytoskeletal reorganization (Fig. 1, reviewed in [1]). Several signaling pathways, such as myosin light chain kinase (MLCK), protein kinase C (PKC), mitogen-activated protein kinases (MAPK), and the Rho family of small GTPases, control the remodeling and maintenance of TJ. TJ not only regulate paracellular transport of nutrients and water, but they also provide a barrier against enteric microbes. Although the exact etiology is unknown, there is ample evidence that epithelial barrier function is compromised in inflammatory bowel disease (IBD) patients. Data from various studies using inert non-metabolized probes indicate that paracellular permeability is increased in Crohn’s Disease (CD) [2]. Furthermore, increased permeability may precede the onset of inflammation [3]. Researchers also found that enteric permeability is increased in 10–54 % of healthy, first-degree relatives of IBD patients [4, 5]. To date, several studies have associated IBD with mutations in the NOD2 gene [6, 7]. However, NOD2 penetrance of the most at-risk genotypes is low [8], and it is likely that cooperation with other genetic factors, such as TJ defects, is required for disease development. Interestingly, Buhner et al. detected increased permeability in IBD patients and family members with NOD2 mutations [9]. Altogether, these findings support the speculation that altered permeability constitutes one of several genetically determined variables that enhances the risk for developing IBD.
Literature
1.
go back to reference Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141:769–776.PubMedCrossRef Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141:769–776.PubMedCrossRef
2.
go back to reference Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Anna Internal Med. 1986;105:883–885. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Anna Internal Med. 1986;105:883–885.
3.
go back to reference Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis. 1999;5:262–270.PubMedCrossRef Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis. 1999;5:262–270.PubMedCrossRef
4.
go back to reference Hollander D. Permeability in Crohn’s disease: altered barrier functions in healthy relatives? Gastroenterology. 1993;104:1848–1851.PubMed Hollander D. Permeability in Crohn’s disease: altered barrier functions in healthy relatives? Gastroenterology. 1993;104:1848–1851.PubMed
5.
go back to reference May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology. 1993;104:1627–1632.PubMed May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology. 1993;104:1627–1632.PubMed
6.
go back to reference Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606.PubMedCrossRef Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606.PubMedCrossRef
7.
go back to reference Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.PubMedCrossRef Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.PubMedCrossRef
8.
go back to reference Hugot JP, Zaccaria I, Cavanaugh J, et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol. 2007;102:1259–1267.PubMedCrossRef Hugot JP, Zaccaria I, Cavanaugh J, et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol. 2007;102:1259–1267.PubMedCrossRef
9.
go back to reference Buhner S, Buning C, Genschel Jet al. Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation? Gut. 2006;55:342–347. Buhner S, Buning C, Genschel Jet al. Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation? Gut. 2006;55:342–347.
10.
go back to reference Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology. 2009;136:551–563.PubMedCrossRef Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology. 2009;136:551–563.PubMedCrossRef
11.
go back to reference Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995;270:1203–1207.PubMedCrossRef Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995;270:1203–1207.PubMedCrossRef
12.
go back to reference Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol. 2010;189:111–126.PubMedCrossRef Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol. 2010;189:111–126.PubMedCrossRef
13.
go back to reference Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–564.PubMed Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–564.PubMed
14.
go back to reference Chang MY, Boulden J, Valenzano MC, et al. Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci. (Epub ahead of print). doi: 10.1007/s10620-012-2147-y. Chang MY, Boulden J, Valenzano MC, et al. Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci. (Epub ahead of print). doi: 10.​1007/​s10620-012-2147-y.
15.
go back to reference Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996;14:69–77.PubMedCrossRef Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996;14:69–77.PubMedCrossRef
16.
go back to reference Pineda-Lucena A, Ho CS, Mao DY, et al. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol. 2005;351:182–194.PubMedCrossRef Pineda-Lucena A, Ho CS, Mao DY, et al. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol. 2005;351:182–194.PubMedCrossRef
17.
go back to reference Cowling BS, Toussaint A, Muller J, Laporte J. Defective membrane remodeling in neuromuscular diseases: insights from animal models. PLoS Genet. 2012;8:e1002595.PubMedCrossRef Cowling BS, Toussaint A, Muller J, Laporte J. Defective membrane remodeling in neuromuscular diseases: insights from animal models. PLoS Genet. 2012;8:e1002595.PubMedCrossRef
18.
go back to reference DuHadaway JB, Lynch FJ, Brisbay S, et al. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem. 2003;88:635–642.PubMedCrossRef DuHadaway JB, Lynch FJ, Brisbay S, et al. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem. 2003;88:635–642.PubMedCrossRef
19.
go back to reference Chang MY, Boulden J, Katz JB, et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 2007;67:7605–7612.PubMedCrossRef Chang MY, Boulden J, Katz JB, et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 2007;67:7605–7612.PubMedCrossRef
20.
go back to reference Okamoto R, Watanabe M. Cellular and molecular mechanisms of the epithelial repair in IBD. Digest Dis Sci. 2005;50:S34–S38.PubMedCrossRef Okamoto R, Watanabe M. Cellular and molecular mechanisms of the epithelial repair in IBD. Digest Dis Sci. 2005;50:S34–S38.PubMedCrossRef
21.
go back to reference Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease—a true paradigm of success? Gastroenterol Hepatol. 2012;8:29–38. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease—a true paradigm of success? Gastroenterol Hepatol. 2012;8:29–38.
22.
go back to reference Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD. AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol. 2009;11:1399–1410.PubMedCrossRef Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD. AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol. 2009;11:1399–1410.PubMedCrossRef
Metadata
Title
Bin1: A New Player in IBD Barrier Dysfunction
Authors
Hyunji Ryu
Daniela Posca
Terrence Barrett
Publication date
01-07-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2228-y

Other articles of this Issue 7/2012

Digestive Diseases and Sciences 7/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.